Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 2/2018

17.07.2017 | Invited Mini Review

Short-Term Use of Injectable Contraception: An Effective Strategy for Safe Motherhood

verfasst von: Suvarna Satish Khadilkar

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Excerpt

Use of contraception is a substantial and effective preventive strategy to reduce maternal mortality, especially in developing countries. Numbers of unintended pregnancies and unmet contraceptive need are still high in many developing countries, and hence abortion-related deaths are also very high. Every two hours a woman dies from an unsafe abortion in India! Hence, the problem of unsafe abortions is especially acute. There were 620,472 reported abortions in 2012; experts say the true number of abortions performed in the country could be as high as 7 million, with two-thirds of them taking place outside authorized health facilities [1]. The global perception is also stark; the number of women with an unmet need for family planning has been projected to grow to 962 million by 2015. …
Literatur
2.
Zurück zum Zitat Singh S, Darroch JE, Ashford LS, et al. Adding it up: the costs and benefits of investing in family planning and maternal and newborn health. New York: Guttmacher Institute and United Nations Population Fund; 2009. Singh S, Darroch JE, Ashford LS, et al. Adding it up: the costs and benefits of investing in family planning and maternal and newborn health. New York: Guttmacher Institute and United Nations Population Fund; 2009.
3.
Zurück zum Zitat Liu L, Becker S, Tsui A, et al. Three methods of estimating births averted nationally by contraception. Popul Stud (Camb). 2008;62:191–210.CrossRef Liu L, Becker S, Tsui A, et al. Three methods of estimating births averted nationally by contraception. Popul Stud (Camb). 2008;62:191–210.CrossRef
4.
Zurück zum Zitat Joshi R, Khadilkar S, Patel M. Global trends in use of long-acting reversible and permanent methods of contraception: seeking a balance. Int J Gynaecol Obstet. 2015;131(Suppl 1):S60–3.CrossRefPubMed Joshi R, Khadilkar S, Patel M. Global trends in use of long-acting reversible and permanent methods of contraception: seeking a balance. Int J Gynaecol Obstet. 2015;131(Suppl 1):S60–3.CrossRefPubMed
5.
Zurück zum Zitat Said S, Omar K, Koetsawang S, et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1987;35:591–610.CrossRefPubMed Said S, Omar K, Koetsawang S, et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1987;35:591–610.CrossRefPubMed
6.
Zurück zum Zitat National Collaborating Centre for Women’s and Children’s Health (UK). NICE clinical guidelines, No. 30. London: RCOG Press; 2005. National Collaborating Centre for Women’s and Children’s Health (UK). NICE clinical guidelines, No. 30. London: RCOG Press; 2005.
7.
Zurück zum Zitat Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera(R). Contraception. 2004;70:11–8.CrossRefPubMed Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera(R). Contraception. 2004;70:11–8.CrossRefPubMed
8.
Zurück zum Zitat Task force on long-acting agents for the regulation of fertility. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisteroneenanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28:1–20. Task force on long-acting agents for the regulation of fertility. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisteroneenanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report. Contraception. 1983;28:1–20.
9.
Zurück zum Zitat Sekadde-Kigondu C, Mwathe EG, Ruminjo JK, et al. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya. East Afr Med J. 1996;73:786–94.PubMed Sekadde-Kigondu C, Mwathe EG, Ruminjo JK, et al. Acceptability and discontinuation of Depo-Provera, IUCD and combined pill in Kenya. East Afr Med J. 1996;73:786–94.PubMed
10.
Zurück zum Zitat Khadilkar S, Sood A, Shivkar KS, et al. Short term use of INJ DMPA: key to successful family planning programme. Contraception and fertility control (EP9.033). BJOG Int J Obstet Gynaecol. 2016;123:170–7. doi:10.1111/1471-0528.14107.CrossRef Khadilkar S, Sood A, Shivkar KS, et al. Short term use of INJ DMPA: key to successful family planning programme. Contraception and fertility control (EP9.033). BJOG Int J Obstet Gynaecol. 2016;123:170–7. doi:10.​1111/​1471-0528.​14107.CrossRef
11.
Zurück zum Zitat Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10:181–202.CrossRefPubMed Schwallie PC, Assenzo JR. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception. 1974;10:181–202.CrossRefPubMed
14.
Zurück zum Zitat Mohllajee AP, Curtis KM. Progestogen-only contraceptive use in obese women. World Health Organization, division of reproductive health, centers for disease control and prevention. US Agency for International Development and National Institute of Child Health and Human Development; 2004. Mohllajee AP, Curtis KM. Progestogen-only contraceptive use in obese women. World Health Organization, division of reproductive health, centers for disease control and prevention. US Agency for International Development and National Institute of Child Health and Human Development; 2004.
Metadaten
Titel
Short-Term Use of Injectable Contraception: An Effective Strategy for Safe Motherhood
verfasst von
Suvarna Satish Khadilkar
Publikationsdatum
17.07.2017
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 2/2018
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-017-1029-9

Weitere Artikel der Ausgabe 2/2018

The Journal of Obstetrics and Gynecology of India 2/2018 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.